Literature DB >> 9021435

Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline.

H J Mascher1, C Kikuta, A Millendorfer, H Schiel, G Ludwig.   

Abstract

A bioavailability study of 2 different selegiline preparations were conducted in 20 healthy volunteers to test the bioequivalence. Almost no bioavailability study of selegiline has been published. As plasma levels of selegiline are very low and the elimination half-life is very short being about 9 minutes, therefore, a very sensitive and selective method for determining the 3 main metabolites desmethylselegiline (DMS), methamphetamine (MA) and amphetamine (A) was developed. After application of a single oral dose of 5 mg selegiline the Cmax values of DMS reached 5-6 ng/ml, of MA 6-7 ng/ml and of A about 2 ng/ml. The AUC infinity values were with DMS about 11 ng/ml x h +/- 4.5, with MA about 130 g/ml x h +/- 50 and with A about 50 ng/ml x h +/- 15. The 90% confidence interval was with logarithmic transformed AUC infinity values 92-107% with DMS, 89-107% with MA, and 84-104% with A. The logarithmic transformed Cmax values showed a 90% confidence interval of 92-127% with DMS, 91-101% with MA, and 90-103% with A. All relevant pharmacokinetic parameters showed bioequivalence with all 3 metabolites (DMS, MA, and A).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9021435

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  5 in total

Review 1.  Metabolites and bioequivalence: past and present.

Authors:  Andre J Jackson; Gabriel Robbie; Patrick Marroum
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

2.  R-deprenyl: pharmacological spectrum of its activity.

Authors:  K Magyar; B Szende; V Jenei; T Tábi; M Pálfi; E Szöko
Journal:  Neurochem Res       Date:  2010-08-20       Impact factor: 3.996

3.  Adolescent HIV-1 transgenic rats: evidence for dopaminergic alterations in behavior and neurochemistry revealed by methamphetamine challenge.

Authors:  Landhing M Moran; Michael Y Aksenov; Rosemarie M Booze; Katy M Webb; Charles F Mactutus
Journal:  Curr HIV Res       Date:  2012-07       Impact factor: 1.581

Review 4.  Drug treatment of patients with insomnia and excessive daytime sleepiness: pharmacokinetic considerations.

Authors:  S Nishino; E Mignot
Journal:  Clin Pharmacokinet       Date:  1999-10       Impact factor: 6.447

Review 5.  Metabolism of monoamine oxidase inhibitors.

Authors:  G B Baker; L J Urichuk; K F McKenna; S H Kennedy
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.